The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001222336p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
1/09/2026
Date registered
Help: Date registered
7/10/2026
Date last updated
Help: Date last updated
7/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
7/10/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Effect of Cryo-Cuff (cryotherapy cuff) therapy on postoperative opioid use in patients undergoing arthroscopic rotator cuff repair surgery: a randomised controlled trial
Scientific title
A randomised controlled trial of Cryo-Cuff (cryotherapy cuff) therapy versus standard care on cumulative opioid consumption, expressed as oral morphine milligram equivalents (OMME), during the first 14 post-operative days in patients undergoing arthroscopic rotator cuff repair surgery
Additional trial identifiers [1] 318167 0
Nil
Universal Trial Number (UTN)
Nil
Trial acronym
CryoCuff Study
Related trial records

Health condition
Health condition(s) studied:
Rotator Cuff tear (full-thickness or high-grade partial-thickness) 343220 0
Post-operative pain following arthroscopic rotator cuff repair 343221 0
Condition category
Condition code
Musculoskeletal 339307 339307 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Cryo-Cuff Therapy (intervention arm) vs standard post-operative care (control arm) following arthroscopic rotator cuff repair (aRCR).
Arm 1: Cryo-Cuff Therapy
- Intervention materials: A cryo-cuff device combining localised cold application with intermittent pneumatic compression, delivering circulating cold water via a gravity-feed cuff applied to the operated shoulder.

- Procedures and activities: Participants are shown correct device use by clinical staff prior to hospital discharge, then self-administer the cryo-cuff at home for post-operative days 0-14, beginning after discharge from the Post-Anaesthetic Care Unit (PACU), in addition to standard multimodal analgesia (discharge medications including paracetamol, ibuprofen, oxycodone and/or tapentadol as clinically indicated). To minimise the risk of cold-related skin injury, use is limited to 20-30 minute sessions rather than continuous wear, participants are instructed to check the skin under the cuff at least every hour during use, and to stop use and seek advice if they notice numbness, skin colour change, excessive discomfort or other adverse skin symptoms.

- Personnel delivering the intervention: Nursing/clinical staff provide initial instruction in hospital; thereafter the device is self-administered by the participant (a carer or family member may assist).

- Mode of delivery: Home-based, self-administered, following in-hospital demonstration.

- Frequency and duration: 20-30 minutes, three to four times daily and after prescribed exercises where comfortable, for post-operative days 0-14; daily duration of use (minutes) is self-recorded in the patient pain and medication diary. Temporary cessation or reduced use is permitted for discomfort, skin symptoms or clinical advice and will be documented.

- Location: Participant's home, following instruction given at Mater Private Hospital Townsville or Morse Orthopaedics.
Personalisation/adaptation: Sessions may be shortened or paused for discomfort, skin symptoms or clinical advice; the prescribed frequency and duration otherwise apply to all intervention participants.

- Adherence/fidelity assessment: Cumulative daily minutes of cryo-cuff use are recorded in the patient diary and reviewed by the research team. A daily skin/adverse-event check is self-completed by the participant in the diary (a simple yes/no question on skin changes, numbness or discomfort from the cryo-cuff), and reviewed by the research team; there is no separate clinical video-call skin review.
Both arms receive standardised, protocolised perioperative analgesia: general anaesthesia with an interscalene block for all participants, confirmed suitable by the treating anaesthetist on the day of surgery, after randomisation, as part of routine pre-operative assessment.
Intervention code [1] 335057 0
Treatment: Devices
Description of the comparator or control
Control arm: Standard post-operative care without cryo-cuff. All participants, regardless of group, receive the same standardised perioperative analgesia protocol: intraoperative fentanyl and/or oxycodone as clinically indicated, oxycodone titration given intravenously or under the skin (subcutaneously) in the Post-Anaesthetic Care Unit (PACU) per the site's PACU pain protocol, and discharge analgesia (paracetamol, ibuprofen, oxycodone and/or tapentadol as clinically indicated). Control-arm participants do not receive a cryo-cuff device. Delivered face-to-face in hospital, then via standard discharge medication at home, over the same 14-day post-operative period as the intervention arm.
Control group
Active

Outcomes
Primary outcome [1] 346532 0
Cumulative opioid consumption, post-operative days 0-14 (oral morphine milligram equivalents, OMME)
Timepoint [1] 346532 0
Post-operative days 0-14
Secondary outcome [1] 466282 0
Oxford Shoulder Score
Timepoint [1] 466282 0
Pre-operative baseline, 6 weeks and 3 months post-surgery (single assessment at each visit - not derived from the twice-daily pain diary)
Secondary outcome [2] 466283 0
Post-operative pain (Visual Analog Scale, VAS)
Timepoint [2] 466283 0
Days 0–7 post-operatively (NRS continues to be recorded to day 14 to support safety/adverse-event monitoring).
Secondary outcome [3] 466284 0
Functional recovery - American Shoulder and Elbow Surgeons (ASES)
Timepoint [3] 466284 0
6 weeks and 3 months post-surgery (single assessment at each visit).
Secondary outcome [4] 466286 0
Functional recovery - Single Assessment Numeric Evaluation (SANE)
Timepoint [4] 466286 0
6 weeks, 3 months post-surgery (single assessment at each visit)
Secondary outcome [5] 466287 0
Date of return to pre-injury baseline activity level, recorded as part of routine post-operative follow-up (Clinical review)
Timepoint [5] 466287 0
Assessed at each follow-up contact throughout the 3-month follow-up period; participants not returned to work/baseline activity by 3 months are censored at last assessment for analysis.
Secondary outcome [6] 466288 0
Patient-reported satisfaction with recovery
Timepoint [6] 466288 0
Day 7 post-operatively, Day 14 post-operatively, and 6 weeks post-surgery
Secondary outcome [7] 466289 0
Incidence of cryo-cuff related adverse events (e.g., cold injury, skin changes, discomfort)
Timepoint [7] 466289 0
Days 0-14 post-operatively
Secondary outcome [8] 467804 0
Incidence of protocol non-compliance
Timepoint [8] 467804 0
Days 0-14 post-operatively.

Eligibility
Key inclusion criteria
Adults aged 18-75 years
- undergoing elective primary arthroscopic rotator cuff repair (aRCR) for acute or chronic full thickness or high-grade partial-thickness tears
- Employed, seeking employment, or functionally active (to assess return-to-work outcomes)
- Residing within the catchment area for post-operative follow-up (Tele health permitted if that is how surgeon chooses to consult)
- Able and willing to comply with post-operative protocols and cryo-cuff use (if applicable)
- Able to provide informed consent
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Previous rotator cuff surgery or revision shoulder procedures
- concurrent major shoulder procedures requiring a different rehabilitation pathway or likely to substantially alter post-operative pain, unless prospectively approved and documented by the Prinicipal Investigator
- Contraindications to cryotherapy (e.g., Raynaud's, cryoglobulinaemia, cold urticaria, peripheral vascular disease)
- Significant cognitive impairment or psychiatric illness impacting protocol adherence
- Active acute or chronic infection involving the shoulder or systemic infection
- Inflammatory arthropathy (e.g., rheumatoid arthritis, lupus)
- Advanced glenohumeral joint arthritis or shoulder instability
- Current substance use disorder (alcohol or drugs)
- Pregnancy or breastfeeding
- Inability to understand or complete outcome assessments due to language or literacy barriers (unless interpretor is requested)
- Inability to consent

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Randomisation is performed via an online randomisation tool at the time of a patient consent. The randomisation sequence is held within the tool and is accessible only to the ORIQL Research Coordinator, who has no role in recruitment or eligibility screening; recruiting/screening staff have no access to the sequence and cannot predict upcoming allocations.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
1:1 allocation using randomly permuted block sizes of 4 and 6 (varied and undiscosed to recruiting staff), generated via an online randomisation tool, with no stratification factors.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Sample size: based on Xiao et al. (2026), a cohort study reporting mean (SD) opioid consumption in the first post-operative week of 115.2 (SD 83.1) mg OMME with cold therapy versus 168.3 (SD 96.0) mg OMME with standard care, a between-group difference of 53.1 mg, consistent with Khan et al. (2024) (55.9 mg difference). Using a pooled SD of 89.8mg, two-sided alpha of 5% and power of 80% the calculated sample size was 45 participants per group (90 total). Allowing for up to 15% loss to follow-up, 53 participants will be recruited per group (106).

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment postcode(s) [1] 46382 0
4812 - Pimlico

Funding & Sponsors
Funding source category [1] 322730 0
Self funded/Unfunded
Name [1] 322730 0
Orthopaedic Research Institute of Queensland - investigator initiated study
Country [1] 322730 0
Australia
Primary sponsor type
Other
Name
Orthopaedic Research Institute of Queensland
Address
Country
Australia
Secondary sponsor category [1] 325652 0
None
Name [1] 325652 0
Address [1] 325652 0
Country [1] 325652 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 321173 0
Mater Misericordiae Ltd Human Research Ethics Committee
Ethics committee address [1] 321173 0
Ethics committee country [1] 321173 0
Australia
Date submitted for ethics approval [1] 321173 0
11/09/2026
Approval date [1] 321173 0
Ethics approval number [1] 321173 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 152906 0
Dr Levi Morse
Address 152906 0
Morse Orthopaedics, 1/50 Fulham Rd Pimlico, Townsville, Queensland, 4812
Country 152906 0
Australia
Phone 152906 0
+61 7 44092090
Fax 152906 0
Email 152906 0
Contact person for public queries
Name 152907 0
Andrea Grant
Address 152907 0
Cowboys Excellence Centre, level 2 tenancy GB, 26 Graham Murray Place, Townsville, Queensland, 4810
Country 152907 0
Australia
Phone 152907 0
+61 7 47550564
Fax 152907 0
Email 152907 0
Contact person for scientific queries
Name 152908 0
Andrea Grant
Address 152908 0
Cowboys Excellence Centre, level 2 tenancy GB, 26 Graham Murray Place, Townsville Queensland 4810
Country 152908 0
Australia
Phone 152908 0
+61 7 47550564
Fax 152908 0
Email 152908 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: De-identified study data is shared only with the study statistician for analysis purposes, per the approved Research Data Management Plan; broader individual participant data sharing is not proposed under the current ethics approval.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.